<?xml version="1.0" ?>
<text author="Omid Hamid, C.  Lance Cowey, Michelle Offner, Mark Faries, Richard  D. Carvajal" dateCollected="2019-11-03" id="autogum_academic_doc507" shortTile="efficacy-safety-tolerability" sourceURL="https://www.mdpi.com/2072-6694/11/11/1642/htm" speakerCount="0" speakerList="none" title="Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma" type="academic">
<head>
<s>
4	CD	4
.	.	.
</s>
<s>
Materials	NNS	Materials
and	CC	and
Methods	NNS	method
</s>
</head>
<p>
<s>
A	DT	a
search	NN	search
was	VBD	be
performed	VBN	perform
of	IN	of
regulatory	JJ	regulatory
and	CC	and
scientific	JJ	scientific
literature	NN	literature
to	TO	to
identify	VB	identify
sources	NNS	source
of	IN	of
clinical	JJ	clinical
data	NNS	datum
to	TO	to
be	VB	be
used	VBN	use
to	TO	to
compare	VB	compare
the	DT	the
efficacy	NN	efficacy
and	CC	and
safety	NN	safety
of	IN	of
BRAFi/MEKi	NNP	BRAFi/MEKi
combination	NN	combination
therapies	NNS	therapy
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
<hi rend="italic">
BRAF	NNP	BrAf
</hi>
-mutant	NN	-mutant
metastatic	JJ	metastatic
melanoma	NN	melanoma
.	.	.
</s>
<s>
The	DT	the
full	JJ	full
details	NNS	detail
of	IN	of
the	DT	the
literature	NN	literature
search	NN	search
are	VBP	be
outlined	VBN	outline
in	IN	in
Table	NNP	table
S4	NNP	S4
.	.	.
</s>
<s>
Four	CD	Four
phase	NN	phase
III	NNP	III
studies	NNS	study
were	VBD	be
identified	VBN	identify
:	:	:
coBRIM	NNP	coBRIM
,	,	,
a	DT	a
phase	NN	phase
III	NN	III
trial	NN	trial
of	IN	of
cobimetinib	NN	cobimetinib
plus	SYM	plus
vemurafenib	NN	vemurafenib
versus	SYM	versus
vemurafenib	NN	vemurafenib
monotherapy	NN	monotherapy
in	IN	in
previously	RB	previously
untreated	VBN	untreated
patients	NNS	patient
with	IN	with
advanced	VBN	advance
<hi rend="italic">
BRAF	NNP	BrAf
</hi>
-mutant	NN	-mutant
melanoma	NN	melanoma
;	:	;
COMBI-d	NNP	COMBI-d
,	,	,
a	DT	a
phase	NN	phase
III	NN	III
trial	NN	trial
of	IN	of
dabrafenib	NN	dabrafenib
and	CC	and
trametinib	NN	trametinib
versus	IN	versus
dabrafenib	NN	dabrafenib
monotherapy	NN	monotherapy
in	IN	in
previously	RB	previously
untreated	VBN	untreated
patients	NNS	patient
with	IN	with
unresectable	JJ	unresectable
stage	NN	stage
IIIC	NN	IIIC
or	CC	or
stage	NN	stage
IV	NN	IV
melanoma	NN	melanoma
with	IN	with
a	DT	a
<hi rend="italic">
BRAF	NNP	BrAf
</hi>
V600E	NN	V600e
or	CC	or
V600K	CD	V600K
mutation	NN	mutation
;	:	;
COMBI-v	NNP	COMBI-v
,	,	,
a	DT	a
phase	NN	phase
III	NN	III
trial	NN	trial
of	IN	of
dabrafenib	NN	dabrafenib
plus	SYM	plus
trametinib	NN	trametinib
versus	SYM	versus
vemurafenib	NN	vemurafenib
monotherapy	NN	monotherapy
in	IN	in
previously	RB	previously
untreated	VBN	untreated
patients	NNS	patient
with	IN	with
unresectable	JJ	unresectable
stage	NN	stage
IIIC	NN	IIIC
or	CC	or
IV	NN	IV
melanoma	NN	melanoma
with	IN	with
<hi rend="italic">
BRAF	NNP	BrAf
</hi>
mutation	NN	mutation
;	:	;
and	CC	and
COLUMBUS	NNP	COLUMBUS
Part	NNP	part
1	CD	1
,	,	,
a	DT	a
phase	NN	phase
III	NN	III
trial	NN	trial
of	IN	of
encorafenib	FW	encorafenib
plus	SYM	plus
binimetinib	FW	binimetinib
versus	SYM	versus
vemurafenib	NN	vemurafenib
or	CC	or
encorafenib	NN	encorafenib
monotherapy	NN	monotherapy
in	IN	in
patients	NNS	patient
with	IN	with
<hi rend="italic">
BRAF	NNP	BrAf
</hi>
-mutant	NN	-mutant
melanoma	NN	melanoma
.	.	.
</s>
<s>
Three	CD	Three
of	IN	of
the	DT	the
identified	VBN	identify
studies	NNS	study
(	-LRB-	(
coBRIM	NNP	coBRIM
,	,	,
COMBI-v	NNP	COMBI-v
,	,	,
and	CC	and
COLUMBUS	NNP	COLUMBUS
Part	NNP	part
1	CD	1
)	-RRB-	)
,	,	,
had	VBD	have
vemurafenib	NN	vemurafenib
960	CD	@card@
mg	NNS	mg
twice	RB	twice
daily	RB	daily
(	-LRB-	(
BID	NNP	BID
)	-RRB-	)
as	IN	as
a	DT	a
control	NN	control
arm	NN	arm
,	,	,
and	CC	and
were	VBD	be
the	DT	the
chief	JJ	chief
sources	NNS	source
of	IN	of
data	NNS	datum
for	IN	for
the	DT	the
comparisons	NNS	comparison
presented	VBN	present
here	RB	here
.	.	.
</s>
<s>
Although	IN	although
the	DT	the
COMBI-d	NNP	COMBI-d
was	VBD	be
identified	VBN	identify
as	IN	as
part	NN	part
of	IN	of
the	DT	the
initial	JJ	initial
literature	NN	literature
search	NN	search
,	,	,
it	PRP	it
was	VBD	be
not	RB	not
included	VBN	include
in	IN	in
the	DT	the
efficacy	NN	efficacy
comparison	NN	comparison
of	IN	of
the	DT	the
cross-trial	JJ	cross-trial
comparison	NN	comparison
due	JJ	due
to	TO	to
the	DT	the
lack	NN	lack
of	IN	of
a	DT	a
vemurafenib	NN	vemurafenib
control	NN	control
arm	NN	arm
.	.	.
</s>
<s>
It	PRP	it
should	MD	should
be	VB	be
noted	VBN	note
,	,	,
however	RB	however
,	,	,
that	IN	that
the	DT	the
outcomes	NNS	outcome
in	IN	in
COMBI-d	NNP	COMBI-d
were	VBD	be
substantially	RB	substantially
similar	JJ	similar
to	TO	to
those	DT	those
in	IN	in
COMBI-v	NNP	COMBI-v
.	.	.
</s>
<s>
The	DT	the
key	JJ	key
design	NN	design
features	NNS	feature
of	IN	of
the	DT	the
three	CD	three
included	VBN	include
phase	NN	phase
III	NNP	III
trials	NNS	trial
are	VBP	be
summarized	VBN	summarize
in	IN	in
Table	NNP	table
5	CD	5
.	.	.
</s>
<s>
To	TO	To
assist	VB	assist
with	IN	with
the	DT	the
completeness	NN	completeness
of	IN	of
the	DT	the
cross-trial	JJ	cross-trial
comparison	NN	comparison
,	,	,
medical	JJ	medical
information	NN	information
requests	NNS	request
were	VBD	be
made	VBN	make
to	TO	to
the	DT	the
registered	VBN	registered
sponsor	NN	sponsor
of	IN	of
cobimetinib	NN	cobimetinib
,	,	,
vemurafenib	NN	vemurafenib
,	,	,
dabrafenib	NN	dabrafenib
,	,	,
trametinib	NN	trametinib
,	,	,
encorafenib	NN	encorafenib
,	,	,
or	CC	or
binimetinib	NN	binimetinib
if	IN	if
any	DT	any
missing	VBG	miss
data	NNS	datum
were	VBD	be
identified	VBN	identify
.	.	.
</s>
</p>
<p>
<s>
The	DT	the
data	NN	datum
sources	NNS	source
for	IN	for
the	DT	the
coBRIM	NNP	coBRIM
and	CC	and
COMBI-v	NNP	COMBI-v
trials	NNS	trial
included	VBD	include
primary	JJ	primary
and	CC	and
secondary	JJ	secondary
publications	NNS	publication
of	IN	of
data	NNS	datum
,	,	,
European	JJ	European
public	JJ	public
assessment	NN	assessment
reports	NNS	report
(	-LRB-	(
EPAR	NNP	EPAR
)	-RRB-	)
,	,	,
U.S.	NNP	U.S.
Food	NNP	Food
and	CC	and
Drug	NNP	drug
Administration	NNP	Administration
(	-LRB-	(
FDA	NNP	FDA
)	-RRB-	)
medical	JJ	medical
review	NN	review
documents	NNS	document
,	,	,
and	CC	and
the	DT	the
current	JJ	current
U.S.	NNP	U.S.
prescribing	NN	prescribe
information	NN	information
(	-LRB-	(
see	VB	see
Table	NNP	table
S5	NNP	S5
,	,	,
which	WDT	which
illustrates	VBZ	illustrate
the	DT	the
data	NN	datum
sources	NNS	source
and	CC	and
cutoff	NN	cutoff
dates	NNS	date
for	IN	for
COMBI-v	NNP	COMBI-v
,	,	,
coBRIM	NNP	coBRIM
,	,	,
and	CC	and
COLUMBUS	NNP	COLUMBUS
trials	NNS	trial
)	-RRB-	)
.	.	.
</s>
<s>
The	DT	the
data	NN	datum
sources	NNS	source
for	IN	for
the	DT	the
COLUMBUS	NNP	COLUMBUS
trial	NN	trial
include	VBP	include
a	DT	a
primary	JJ	primary
publication	NN	publication
,	,	,
U.S.	NNP	U.S.
prescribing	VBG	prescribe
information	NN	information
,	,	,
and	CC	and
Array	NNP	array
BioPharma	NNP	BioPharma
data	NNS	datum
on	IN	on
file	NN	file
.	.	.
</s>
</p>
<p>
<s>
The	DT	the
efficacy	NN	efficacy
outcomes	NNS	outcome
presented	VBN	present
are	VBP	be
PFS	NNP	PFS
,	,	,
objective	NN	objective
response	NN	response
rate	NN	rate
(	-LRB-	(
ORR	NNP	ORR
)	-RRB-	)
,	,	,
duration	NN	duration
of	IN	of
response	NN	response
(	-LRB-	(
DOR	NNP	DOR
)	-RRB-	)
per	IN	per
investigator	NN	investigator
assessment	NN	assessment
,	,	,
and	CC	and
OS	NNP	OS
.	.	.
</s>
<s>
The	DT	the
assessments	NNS	assessment
of	IN	of
the	DT	the
tumor	NN	tumor
response	NN	response
across	IN	across
the	DT	the
studies	NNS	study
were	VBD	be
performed	VBN	perform
using	VBG	use
Response	NN	response
Evaluation	NNP	evaluation
Criteria	NNP	Criteria
in	IN	in
Solid	NNP	solid
Tumors	NNP	Tumors
(	-LRB-	(
RECIST	NNP	RECIST
)	-RRB-	)
version	NN	version
1.1	CD	@card@
.	.	.
</s>
</p>
<p>
<s>
The	DT	the
safety	NN	safety
comparisons	NNS	comparison
were	VBD	be
made	VBN	make
using	VBG	use
the	DT	the
adverse	JJ	adverse
event	NN	event
(	-LRB-	(
any	DT	any
untoward	JJ	untoward
medical	JJ	medical
occurrence	NN	occurrence
regardless	NN	regardless
of	IN	of
causal	JJ	causal
relationship	NN	relationship
)	-RRB-	)
and	CC	and
adverse	JJ	adverse
drug	NN	drug
reaction	NN	reaction
(	-LRB-	(
noxious	JJ	noxious
and	CC	and
unintended	JJ	unintended
responses	NNS	response
with	IN	with
at	IN	at
least	JJS	least
a	DT	a
reasonable	JJ	reasonable
possibility	NN	possibility
of	IN	of
a	DT	a
causal	JJ	causal
relationship	NN	relationship
)	-RRB-	)
data	NNS	datum
.	.	.
</s>
<s>
The	DT	the
adverse	JJ	adverse
event	NN	event
data	NNS	datum
included	VBD	include
the	DT	the
overall	JJ	overall
summaries	NNS	summary
(	-LRB-	(
comprising	VBG	comprise
all-grade	JJ	all-grade
,	,	,
serious	JJ	serious
,	,	,
and	CC	and
grade	NN	grade
3/4	CD	@card@
AEs	NNP	AEs
,	,	,
and	CC	and
AEs	NNP	AEs
leading	VBG	lead
to	TO	to
death	NN	death
,	,	,
dose	NN	dose
interruption/modification	NN	interruption/modification
,	,	,
and	CC	and
discontinuation	NN	discontinuation
)	-RRB-	)
and	CC	and
the	DT	the
incidence	NN	incidence
of	IN	of
specific	JJ	specific
all-grade	NN	all-grade
and	CC	and
grade	NN	grade
3/4	CD	@card@
AEs	NNP	AEs
by	IN	by
individual	JJ	individual
preferred	VBN	prefer
terms	NNS	term
per	IN	per
the	DT	the
MedDRA	NNP	MedDRA
dictionary	NN	dictionary
.	.	.
</s>
<s>
All	DT	all
studies	NNS	study
utilized	VBD	utilize
the	DT	the
National	NNP	National
Cancer	NNP	Cancer
Institute	NNP	Institute
(	-LRB-	(
NCI	NNP	NCI
)	-RRB-	)
Common	NNP	Common
Terminology	NNP	Terminology
Criteria	NNP	Criteria
for	IN	for
Adverse	NNP	Adverse
Events	NNPS	Events
(	-LRB-	(
CTCAE	NNP	CTCAE
)	-RRB-	)
to	TO	to
assess	VB	assess
severity	NN	severity
.	.	.
</s>
<s>
The	DT	the
coBRIM	NNP	coBRIM
and	CC	and
COMBI-v	NNP	COMBI-v
trials	NNS	trial
used	VBN	use
version	NN	version
4.0	CD	@card@
,	,	,
whereas	IN	whereas
the	DT	the
COLUMBUS	NNP	COLUMBUS
trial	NN	trial
used	VBN	use
version	NN	version
4.03	CD	@card@
.	.	.
</s>
<s>
The	DT	the
primary	JJ	primary
source	NN	source
of	IN	of
data	NNS	datum
on	IN	on
adverse	JJ	adverse
drug	NN	drug
reactions	NNS	reaction
was	VBD	be
the	DT	the
available	JJ	available
U.S.	NNP	U.S.
prescribing	VBG	prescribe
information	NN	information
.	.	.
</s>
<s>
The	DT	the
additional	JJ	additional
adverse	JJ	adverse
event	NN	event
data	NNS	datum
for	IN	for
the	DT	the
dabrafenib	NN	dabrafenib
plus	,	plus
trametinib	JJ	trametinib
combination	NN	combination
was	VBD	be
derived	VBN	derive
from	IN	from
the	DT	the
COMBI-d	NNP	COMBI-d
trial	NN	trial
.	.	.
</s>
<s>
For	IN	for
the	DT	the
cobimetinib	NN	cobimetinib
plus	SYM	plus
vemurafenib	NN	vemurafenib
combination	NN	combination
,	,	,
the	DT	the
coBRIM	NNP	coBRIM
trial	NN	trial
was	VBD	be
utilized	VBN	utilize
.	.	.
</s>
<s>
The	DT	the
COLUMBUS	NNP	COLUMBUS
study	NN	study
was	VBD	be
utilized	VBN	utilize
as	IN	as
a	DT	a
source	NN	source
of	IN	of
additional	JJ	additional
information	NN	information
for	IN	for
adverse	JJ	adverse
events	NNS	event
for	IN	for
the	DT	the
encorafenib	NN	encorafenib
plus	SYM	plus
binimetinib	NN	binimetinib
combination	NN	combination
.	.	.
</s>
</p>
</text>
